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Ritodrine- and terbutaline-induced hypokalemia in preterm labor:
Mechanisms and consequences. The effects of ritodrine and terbutaline
on potassium homeostasis, renal function, and cardiac rhythm were
assessed in women treated with these drugs for preterm labor. Timed
blood and urine samples were obtained for two hours before and during
six hours of intravenous ritodrine (N = 5) and terbutaline (N = 5)
administered in pharmacologically equivalent doses. No differences were
found in any parameters affecting potassium homeostasis or renal function
between these drugs. A decrease in mean plasma potassium of 0.9
mEq/liter occurred after 30 minutes of drug infusion (4.2 0.1 to 3.3
0.1 mEq/liter, P < 0.005) before any significant changes in plasma glucose
(75.0 4.7 to 93.7 6.1 mg/dl, P = NS) or plasma insulin (12.4 6.0 to
28.4 5.1 mU/mi, P = NS). The mean plasma potassium after four hours
of drug infusion was 2.5 0.1 mEq/liter. Plasma insulin rose to a level
known to induce cellular potassium uptake (39.2 7.7 mU/mi) after 60
minutes of drug therapy and remained at this level for four hours.
Hyperlactatemia occurred at four hours (4.7 0.8 mmol/liter) and the
plasma lactate/pyruvate ratio increased in a 10:1 ratio. Both drugs
significantly reduced glomerular filtration rate, sodium, potassium, and
chloride excretion and urinaly flow rate. Changes in acid-base homeosta-
sis, plasma aldosterone, or renal potassium excretion did not contribute to
ritodrine- or terbu,aline-induced hypokalemia. In 83 women with preterm
labor randomly assigned to ritodrine (N = 42) or terbutaline (N = 41), the
maximum decrease in plasma potassium occurred after six hours of drug
infusion. During Holter monitoring, 3 of 14 women treated with ritodrine
or terbutaline developed symptomatic cardiac arrhythmias at the lowest
plasma potassium, while no women treated with saline and morphine (N =
12) developed cardiac arrhythmias (P = 0.14). We conclude that ritodrine
and terbutaline induce profound hypokalemia by stimulating cellular
potassium uptake and both drugs cause significant renal sodium and fluid
retention and cardiac arrhythmias. Careful monitoring of electrolytes,
fluid balance, and cardiac rhythm should occur during tocolytic therapy
with ritodrine or terbutaline.
Ritodrine hydrochloride and terbutaline sulfate are the two
B-adrenergic drugs most commonly used in the United States to
inhibit preterm labor [1—3]. Ritodrine and terbutaline are primar-
ily B2-selective in their adrenergic effects, resulting in uterine and
bronchiole smooth muscle relaxation. Although both drugs may
induce profound hypokalemia in women treated with these agents
for preterm labor, the mechanisms, duration and consequences of
hypokalemia in these women have not been completely elucidated
[4—8]. Indeed, B2-adrenergic stimulation has the potential to
affect potassium homeostasis by numerous mechanisms.
Ritodrine or terbutaline therapy may increase pancreatic insu-
lin release either due to direct B2-receptor stimulation of pancre-
atic islet cells [9] or due to increases in blood glucose resulting
from B-adrenergic-mediated glycogenolysis and gluconeogenesis
in the liver [10, 11]. Increases in plasma insulin could stimulate
cellular potassium uptake [12]. Changes in blood glucose and
insulin during ritodrine or terbutaline have been the only factors
studied to explain the profound hypokalemia produced by these
drugs. However, 13-adrenergic stimulation in muscle cells may
directly induce cellular potassium uptake by producing increases
in intracellular cAMP which increase the activity of the Na,K-
ATPase pump [121. In addition, plasma renin activity may in-
crease from beta-adrenergic stimulation leading to increases in
plasma aldosterone that could enhance renal potassium excretion
in the distal nephron [13] or exert a permissive effect on extra-
renal cellular potassium uptake [14].
Therapy with ritodrine and terbutaline has been complicated by
pulmonary edema, lactic acidosis and tachyarrhythmias in women
treated with these drugs during preterm labor [8]. It is possible
that these drugs cause significant renal sodium and water reten-
tion which could contribute to pulmonary edema. However, the
renal effects of B-adrenergic drugs in pregnant women have not
been studied. Whether lactic acidosis is due to tissue hypoperfu-
sion from hypotension associated with B-adrenergic-mediated
vasodilation or is due to over-production of lactic acid from
B-adrenergic induced muscle glycogenolysis is unknown. Meta-
bolic acidosis during infusion of these drugs could attenuate
cellular potassium uptake. Finally, no studies have examined
whether a decrease in plasma potassium is associated with cardiac
arrhythmias.
The purpose of this study is to examine the effects of ritodrine
and terbutaline on potassium homeostasis, renal function, urinary
electrolyte excretion and cardiac rhythm in women being treated
with these agents for preterm labor in order to better delineate
the mechanisms for hypokalemia induced by these drugs.
Methods
This study was limited to pregnant women age 18 or older,
between 24 to 36 weeks of gestation who gave written informed
consent to an IRB-approved protocol. All women had the acute
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onset of preterm labor defined as regular uterine contractions
occurring at intervals of < 10 minutes, palpated or recorded for at
least 30 minutes by external tocography and with evidence on
pelvic exam of cervical effacement or dilation. All women were
intitially given an intravenous bolus of 300 ml of 0.45% normal
saline followed by 100 mllhr of this fluid. Women were excluded
if they had active vaginal bleeding, preeclampsia, intrauterine
infection, known maternal diabetes mellitus or an admission
blood sugar > 200 mg/dl, maternal cardiac disease, maternal renal
disease, maternal hypothyroidism, maternal hypertension, anemia
defined as a hematocrit < 30%, twin gestation, fetal malforma-
tion, or a condition limiting the chance of successful of tocolytic
therapy, such as an incompetent cervix, ruptured membranes,
advanced labor, or an untreated urinary tract infection. In addi-
tion, no woman had any prior administration of either ritodrine or
terbutaline during the current pregnancy.
The patients were randomized to receive either ritodrine
hydrochloride (Yutopar®, Astra Pharmaceutical Products, West-
boro, MA, USA) or terbutaline sulfate (Brethine®, Geigy Phar-
maceuticals, Ardsley, NY, USA). Ritodrine therapy was initiated
intravenously at 100 j.tglmin and increased by 50 igImin every 10
minutes up to a maximum of 350 jtgImin or until uterine
contractions ceased. Terbutaline sulfate therapy was initiated at
10 jsglmin and increased by 5 jtgImin up to a maximum of 35
jig/mm or until uterine contractions ceased. The doses of rito-
drine and terbutaline were chosen to be pharmacologically equiv-
alent, since earlier work indicated that terbutaline is 10 times
stronger than ritodrine in stimulating B-adrenergic receptors [15].
Both intravenous infusions were continued for 12 hours, after
which the oral form of each drug was initiated and continued until
38 weeks of gestation or childbirth. Oral ritodrine therapy was
initially started at 20 mg every four hours, and terbutaline sulfate
therapy was initiated at 5 mg every four hours for the first day and
thereafter administered every six hours.
Women in preterm labor were studied utilizing three protocols.
Protocol 1. Effects of intravenous ritodrine or terbutaline on
potassium and acid-base homeostasis and renal function. Ten
women randomly assigned to either drug were studied for two
hours before initiation of intravenous ritodrine (N = 5) or
terbutaline (N = 5) and for four hours after initiation of either
drug. Timed, 30-minute urine samples for urinary sodium, potas-
sium, chloride, creatinine and osmolality were obtained for two
hours before and four hours after initiation of either drug in all
ten women and for 12 hours in five of the ten women. In the
12-hour study, three women received ritodrine and two received
terbutaline. When necessary, foley catheters were utilized to
assure adequate urine samples. All women were placed in a left
lateral position to maximize glomerular filtration and a 24-hour
Holter monitor was attached. In addition, blood was obtained
before ritodrine and terbutaline infusion and at frequent timed
intervals thereafter for four hours. Blood samples were obtained
to measure plasma sodium, potassium, chloride, CO2 content,
glucose, creatinine, calcium, phosphorus, uric acid, insulin, venous
pH, lactate, aldosterone and renin activity.
Protocol 2. Effects of oral ritodrine and terbutaline on plasma
potassium and glucose homeostasis. To determine whether the
hypokalemic effects of ritodrine and terbutaline are sustained
upon conversion to the oral medication, 83 women were random-
ized to receive ritodrine or terbutaline, and plasma potassium and
glucose were determined every six hours for 24 hours. All patients
received either intravenous ritodrine or terbutaline for 12 hours
followed by conversion to the oral drug form as outlined in
Protocol 1. The 10 patients studied during Protocol I are included
in this randomization.
Protocol 3. Effects of ritodrine and terbutaline on cardiac rhythm.
To correlate the hypokalemic effects of ritodrine and terbutaline
with cardiac arrhythmias, 24-hour Holter monitor recordings of
the 10 women above and 4 additional women treated with either
ritodrine and terbutaline were compared to Holter recordings
obtained from 12 women admitted in preterm labor who were
treated with intravenous 0.45% normal saline at the same rate but
given intravenous morphine rather than ritodrine or terbutaline.
In addition, each patient served as her own control since the
Holter monitor was placed for two hours prior to initiation of drug
infusion. Baseline electrocardiographic diagrams were performed
before the initiation of either drug.
Laboratory methods
Plasma sodium and potassium were measured by flame pho-
tometry (Instrument Labs, Lexington, MA, USA). Chloride, CO2
content, glucose and creatinine were measured by spectrophoto-
metric methods, utilizing Guilford/Corning reagents and a Guil-
ford semi-automated spectrophotometer (Guilford Systems,
Oberlin, OH, USA). Pyruvate and lactate were measured using
enzymatic methods [16], utilizing a Dupont Autoanalyzer (Wil-
mington, DE, USA). Venous pH was measured on an Instrument
Labs 1302 arterial blood gas machine. Aldosterone was measured
on ethyl acetate extracts of plasma after chromatography on
celite-ethylene glycol microcolumns. Radioimmunoassay was per-
formed using aldosterone-1, 2, 6, 7-H3 (New England Nuclear
Corp., North Billerica, MA, USA), and a sensitive sheep anti-
aldosterone antibody (Radioassay Systems Laboratories, Carson,
CA, USA). Separation of unbound aldosterone was performed
with a dextran-charcoal suspension. Sensitivity was 5 pg per tube
or 1.5 ng/dl. Assay recoveries were 93 to 97% using H3 aldoste-
rone spiked serum. Intra- and interassay precision was 6% and
9.6% coefficient of variation, respectively. The normal adult
reference range is 2 to 20 ng/dl. Plasma renin activity was
estimated using the Rianen Angiotensin I Radioimmunoassay Kit
(New England Nuclear). Recovery of added angiotensin I was 95
to 100%. Intra-assay precision was 8.7% and 5.2% coefficient of
variation for low and high plasma pool replicators. Sensitivity was
approximately 30 pglml. Plasma renin activity is expressed as ng of
angiotensin I generated/ml/hr. The normal adult reference range
is 20 to 160 ng/ml/hr. Insulin was measured using the "Coat-a-
count" Insulin Radioimmunoassay Kit (Diagnostic Products
Corp., Los Angeles, CA, USA). The assay is performed on
undiluted plasma in antibody-coated tubes. Sensitivity was ap-
proximately 2 jsU/ml and intra-assay precision was 7%. Recovery
from insulin spiked sera was 100%. The normal adult reference
range was 0 (unmeasurable) to 30 jsU/ml.
Statistical analysis
Data were analyzed utilizing the Student's (-test for paired and
unpaired data to examine the effects of both drugs after two
minutes and to examine differences between the two drug groups.
Repeated measures analysis of variance was utilized for changes
in all parameters over time. Fisher's exact test was used to analyze
differences on the cardiac effects of the two drugs compared to
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saline-treated, control patients. A P value < 0.05 was considered
significant.
Results
There were no significant differences in any blood level or renal
function parameter between the five women treated with ritodrine
and the five women treated with terbutaline during the first four
hours of drug infusion. This is presumably due to pharmocologic
equivalency of the two drugs at the dosing concentration used in
this study [15]. Although terbutaline is 10 times more potent than
ritodrine, it was used in 1/10 the dose during the infusion period
yielding similar physiologic effects. Thus, for simplicity, the five
women treated with ritodrine and the five women treated with
terbutaline are grouped together for statistical analysis. The data
presented are the mean standard error for all 10 patients.
Effects of intravenous ritodrine and terbutaline on plasma
potassium
The effects of ritodrine and terbutaline on plasma potassium
are shown in Figure 1. The mean SEM potassium level before i.v.
drug infusions was 4.2 0.1 mEq/liter. Within two minutes of
starting these drugs, the plasma potassium had decreased to 4.0
0.1 mEq/liter (P < 0.05). After 60 minutes of drug infusion, the
mean serum potassium was 2.9 0.1 mEq/liter, for a mean
decrease after one hour of 1.3 0.1 mEq/liter (P < 0.001).
Thereafter, the serum potassium decreased but at a much slower
rate, and after four hours of drug infusion the mean serum
potassium was 2.5 0.1 mEq/Iiter (P < 0.001). The majority of
the decrease in serum potassium (76%) occurred during the first
hour of drug infusion, with only a 24% decrease during the last
three hours of intravenous infusion.
Effects of i. v. ritodrine and terbutaline on glucose and insulin
The effects of these drugs on plasma glucose and insulin are
shown in Figure 2. The baseline plasma glucose before drug
infusion was 75.0 4.7 mg/dl (4.2 mmol/liter) and it increased to
103.3 6.1 mg/dl (5.2 mmol/liter) after 40 minutes of i.v. infusion
(P < 0.05). After 60 minutes of infusion, the mean plasma glucose
was 108.0 10.4 mg/dl (6.0 mmol/liter) and peaked at 142.0 9.0
mgldl (7.9 mmol/liter) after 120 minutes. Plasma insulin before
drug infusion was 12.4 6.0 i.tU/mI and increased significantly to
31.5 5.2 tU/m1 after 40 minutes of drug infusion (P < 0.05).
Plasma insulin reached a mean level of 39.2 7.7 jsU/ml after 60
minutes of drug infusion, a level known to induce cellular
potassium uptake in non-pregnant patients [171. The insulin level
peaked after 90 minutes of drug infusion and remained elevated
above 40 j.tU/ml for the remainder of the four-hour drug infusion.
The early changes in plasma potassium, glucose and insulin
during i.v. drug infusions are shown in Figure 3. The mean plasma
potassium concentration decreased from 4.2 mEq/liter to 3.3
mEq/liter after 30 minutes (P < 0.005), a change of 0.9 mEq/liter,
before any significant changes in glucose or insulin occurred.
There were no significant changes in plasma sodium, chloride,
creatinine, calcium, phosphorus, uric acid, or plasma osmolality at
any time during the drug infusions.
Effects of i. v. ritodrine and terbutaline on bicarbonate, lactate and
pH
The mean plasma bicarbonate level measured as CO2 content
decreased from 19.0 0,7 mEq/liter (mmol/liter) at the start of
the drug infusions to 16.2 0.8 mEq/liter after 240 minutes of
drug infusion (Fig. 4). Plasma lactate increased from a mean value
before drug infusions of 1.2 0.3 mmol/liter to 4.7 0.8
mmol/liter after 240 minutes of drug infusion. The plasma lactate:
pyruvate ratio increased in a 10:1 ratio at all time points during
the 240 minutes of drug infusion. There was no change in venous
pH during four hours of infusion. The 3 mmol/liter mean decrease
in serum bicarbonate after 240 minutes of drug infusion was
equivalent to the mean increase in plasma lactate of 3.7 mmol/
liter.
Effects of i. v. ritodrine and terbutaline on plasma renin activity
and aldosterone
The mean plasma renin activity before drugs was 9.4 1.3
ng/ml/hr, and it increased significantly by 90 minutes and peaked
at 23.5 1.7 nglml/hr after 240 minutes (Fig. 5). The mean
plasma aldosterone concentration decreased as expected with the
decrease in plasma potassium during the first 40 minutes of drug,
and then it increased concomitantly as plasma renin activity
increased during the next 80 minutes, but none of these changes
in plasma aldosterone were significant (Fig. 5).
Effects of oral ritodrine and terbutaline on plasma potassium and
glucose
The hypokalemic effects of intravenous ritodrine and terbutal-
me began to diminish during the last six hours of infusion (Table
1). At 12 hours (end of infusion) and at 18 hours (6 hr after first
oral dose), the mean plasma potassium had returned to approxi-
mately 85% and 96% of the pre-drug levels, respectively. At 24
hours the plasma potassium in the ritodrine treated group had not
yet increased to the baseline level while the plasma potassium in
the terbutaline group was back to baseline. However, there were
no significant differences in plasma potassium at any time period
between the ritodrine and terbutaline treated groups.
The mean plasma glucose was higher after six hours of intra-
venous terbutaline compared to intravenous ritodrine, but the
physiologic significance of this increase at only one time period is
unclear.
_t____7/ I I I I0 10 20 30 40 50 60 90 120 240
Time, minutes
Fig. 1. Effects of ritodrine and terbutaline on plasma potassium during the
first four hours of intravenous administration of the drugs. Data are
expressed as mean su. < 0.05 vs time 0.
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Effects of i. v. ritodrine and terhutaline on renal flinction
The renal effects during the first four hours of intravenous drug
infusion are listed in Table 2. Both drugs produced significant
decreases in the glomerular filtration rate measured as creatinine
clearance and significant decreases in sodium, potassium, and
chloride excretion and the urinary flow rate. The urinary osmo-
lality increased from a baseline of 340 mOsm/kg H20 to 663
mOsm/kg H20 after four hours despite no change in plasma
osmolality. Five out of the 10 women were followed for up to 12
hours after initiation of drug therapy. Although the decreases in
sodium, potassium and chloride excretion and urinary flow rate
persisted for 12 hours, the creatinine clearance improved to
baseline at approximately eight hours after initiating drug infu-
sion. The mean fluid gain after 12 hours in these women was 2.3
0.2 liters.
Changes in systemic hemodynamics associated with B2- sympa-
thomimetic-induced vasodilation were associated with decreases
in creatinine clearance. The mean blood pressure prior to drug
infusion was 119/69 10/4, and decreased to a mean blood
pressure of 97/45 6/3 after 30 minutes of drug infusion (P <
0.01) and to 94/43 5/5 after 90 minutes of drug infusion (P <
0.001). The lower blood pressures were sustained throughout the
first eight hours of intravenous infusion, but began to increase by
the end of the 12 hours intravenous drug infusion and returned to
normal baseline levels on oral therapy.
Effects of ritodrine and terbutaline on cardiac rhythm
The effects of these drugs on cardiac rhythm are listed in Table
3. Baseline EKGs were normal in all 14 women treated with either
ritodrine or terbutaline and in the 12 control women who received
intravenous saline and morphine. Holter monitoring before rito-
drine or terbutaline infusion demonstrated no arrhythmias while
these women were in active preterm labor. Thereafter, one
woman, after three to four hours of i.v. terbutaline, developed
symptomatic supraventricular tachycardia and junctional rhythms
at the nadir of her plasma potassium at 2.2 mEq/liter (Table 3). In
addition, this woman developed multifocal aberrant premature
atrial beats and unifocal ventricular premature beats. Another
woman receiving i.v. ritodrine after three hours developed symp-
tomatic unifocal premature atrial and premature ventricular beats
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Fig. 2. Effects of ritodrine and terbutaline on
plasma glucose (0) and plasma insulin (•)
during the first four hours of intravenous
administration of the drugs. Data are expressed
as mean SE. *p < 0.05 vs. time 0.
Fig. 3. The early effects of intravenous ritodrine
and terbutaline on plasma potassium (U), glucose(0) and insulin (•). Data are expressed as
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Fig. 5. Changes in plasma renin activity and plasma aldosterone during the
first four hours of intravenous ritodrine and terbutaline. Data are expressed
as mean SE. *D< 0.05 renin vs. time 0.
at the nadir of her plasma potassium at 2.1 mEq/liter (Table 3). A
third woman treated with terbutaline developed symptomatic
unifocal premature atrial beats. All arrhythmias developed within
the first four hours of drug infusion when the plasma potassium
had maximally decreased. The arrhythmias disappeared after the
plasma potassium increased during conversion to oral therapy. No
women in the control group treated with saline or morphine
developed arrhythmias. However, the incidence of arrhythmias in
the group treated with ritodrine and terbutaline was not statisti-
cally different from the control group (P = 0.14).
Discussion
It is clear from these studies that therapeutic doses of intrave-
nous ritodrine and terbutaline which inhibit preterm labor rapidly
induce hypokalemia. Indeed, the plasma potassium decreased
significantly just two minutes after initiation of intravenous rito-
drine or terbutaline. After 15 minutes of drug infusion, the plasma
potassium decreased by 0.5 mEq/liter and further decreased by 1.3
NS
Ohr 4hr
Venous pH
Fig. 4. Effects of ritodrine and terbutaline on
acid-base parameters after four hours of
intravenous administration. Data are expressed
as mean SE.
mEq/liter after 60 minutes. Possible mechanisms for a drug-
induced decrease in plasma potassium include a shift of potassium
from the extracellular fluid into the intracellular fluid and/or
increased urinary or gastrointestinal potassium excretion. No
stool samples were obtained during these studies, so it is unknown
whether gastrointestinal potassium excretion is enhanced by these
drugs.
Catecholamines modulate extrarenal potassium homeostasis
18, 19]. Early animal and human studies infusing intravenous
epinephrine showed an initial transient increase in serum potas-
sium due to potassium release from liver cells, but thereafter
significant decreases in serum potassium were demonstrated
presumably due to B2-adrenergic-mediated cellular potassium
[20—22]. This bi-phasic response was blocked by B-adrenergic
receptor antagonists such as propanolol [20]. However, in our
study a bi-phasic potassium response to either ritodrine or
terbutaline was not demonstrated. In addition, the mean plasma
potassium 30 minutes after drug infusion decreased by 0.9 mEq/
liter before any significant rise in blood glucose and insulin. These
observations suggest that ritodrine and terbutaline may directly
stimulate cellular potassium uptake. Beta-adrenergic drugs pre-
sumably decrease plasma potassium by B2-receptor stimulation of
adenylate cyclase which increases intracellular cAMP which acti-
vates Na,K-ATPase leading to cellular potassium uptake [23].
Increases in plasma glucose and plasma insulin levels during
ritodrine and terbutaline infusion may have contributed to a
decrease in plasma potassium in these patients. Beta-adrenergic
stimulation could increase plasma glucose and insulin by several
mechanisms. Beta-adrenergic stimulation in mammalian liver
activitates glycogenolysis and gluconeogenesis, contributing to
increases in plasma glucose which could stimulate pancreatic
insulin release [10]. These effects in cats are blocked by B-adren-
ergic antagonists but not a-adrenergic antagonists, suggesting
specific B-adrenergic effects [24]. In addition, the human liver
contains predominantly B2-adrenergic receptors with a lesser
population of cs1-adrenergic subtypes [25]. Earlier studies utilizing
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Table 1. Effects of ritodrine versus terbutaline on potassium and glucose
Time hours
Parameter Drug N 0 6 12 18 24
Potassium Ritodrine 42 3.67 0.05 2.68 0.04 3.17 0.05 3.56 0.08 3.52 0.06
Potassium Terbutaline 41 3.56 0.05 2.52 0.05 3.03 0.05 3.39 0.11 3.74 0.07
Glucose Ritodrine 42 90 4 151 6 167 6 128 6 119 6
Glucose Terbutaline 41 96 5 189 ioa 186 8 139 6 121 5
Data are expressed as mean SE at all times.
a P < 0.05 ritodrine vs. terbutaline.
Table 2. Effects of ritodrine and terbutaline on renal function
Pre-drug
Drug infusion
1.5 hours 4.0 hours
Creatininc clearance 114.5 16.3 70.8 6.4a 91.8 11.3
mi/mm
Sodium excretion 199.1 37.9 78.8 17.Oa 80.0 14.8
p.Eq/min
Potassium excretion 66.9 8.9 28.3 3•5a 30.1 3.8a
p.Eq/min
Chloride excretion 181.1 34.2 67.8 21.P 51.3 12.1'
p.Eq/min
Urine flow rate 3.6 1.4 1.2 0.2 0.9 0.2
mi/mm
Urine osmolality 340 98 289 31 663 53
mOsm/Kg H20
a P < 0.05 compared to pre-drug.
ritodrine or hexoprenaline to inhibit preterm labor demonstrated
that blood glucose and insulin rise without any significant changes
in glucagon, human placental lactogen or human chorionic gona-
datotropin [26, 27]. In addition, a fall in plasma alanine occurred
during salbutamol therapy to inhibit preterm labor, suggesting
that hepatic gluconeogenesis was also stimulated by these drugs
[281. Thus, pancreatic insulin release could be stimulated by a rise
in plasma glucose from hepatic glycogenolysis and/or gluconeo-
genesis.
Increases in plasma insulin could also occur due to direct
B2-adrenergic stimulation of pancreatic insulin release. Studies in
dogs have shown that B-adrenergic agonists infused directly into
the pancreas stimulate pancreatic insulin release [29]. Similar
changes have been found in rat islet cells incubated with epineph-
rine [30] and in sheep given intravenous isoproterenol [31]. In
addition, two human studies have shown that B-adrenergic stim-
ulation directly stimulates insulin release [29, 32]. Thus, B-adren-
ergic agents can raise plasma insulin secondary to either increases
in glucose or by directly stimulating pancreatic insulin release.
Increases in plasma insulin probably contributed to cellular
potassium uptake during the infusion of ritodrine and terbutaline.
The basal plasma insulin level mediates cellular potassium uptake
since somatostatin infusion in animals and humans suppresses
basal insulin levels inducing a rise in serum potassium of 0.5
mEq/liter [33]. Additional studies have shown that raising the
plasma insulin level in the fasting state to approximately 25 jsU/ml
attenuates the rise in serum potassium after a potassium load [34].
Zierler and Rabinowitz originally calculated that a plasma level of
40 1.tU/ml would be required to shift potassium from the extra-
cellular into the intracellular compartment [17] and studies of
intravenous insulin by glucose clamp techniques, which produced
Table 3. Results of 24-hour Holter monitoring
Arrhythmia N
Time
hr
K
mEq/liter
1. Supraventricular tachycardia ia 4 2.20
2. Premature atrial beats
a. Multifocal, aberrant ia 1 2.35
b. Unifocal, occasional 1h 3 2.10
c. Unifocal, frequent 1 1 3.15
3. Junctional rhythm i' 3 2.20
4. Premature ventricular beats
a. Unifocal, rare ia 0.5 2.95
b. Unifocal, occasional l' 3 2.10
a Same patient.
Same patient.
a mean plama insulin level of 37 U/ml produced a 0.5 mEq/liter
decrease in serum potassium over a two-hour period [35]. In
contrast, intramuscular and subcutaneous insulin that increased
the plasma insulin to 45 /LU/ml for three hours produced no
decrease in serum potassium in normal subjects [36]. In addition,
intravenous insulin infusion in Type I diabetics produced no
decrease in the serum potassium over several hours despite
reaching a mean plasma insulin level of 90 U/ml [37]. In our
study, the mean plasma insulin reached 40 .tU/ml after 60 minutes
of drug infusion and that level persisted for the next three hours.
It is possible that the decrease in plasma potassium in our study is
in part due to insulin-mediated shifts of potassium into the
intracellular compartment during ritodrine and terbutaline infu-
sion. No changes in plasma osmolality occurred to attenuate
cellular potassium uptake [38].
Both ritodrine and terbutaline induced hyperlactatemia after
four hours of drug infusion. Ritodrine and terbutaline have been
reported to produce hyperlactatemia by unknown mechanisms
[39, 40]. In our study, the starting plasma bicarbonate level was
19.6 mEq/liter, consistent with the renal adaptation to chronic
respiratory alkalosis which occurs in normal pregnancies [41, 42].
During the first four hours of drug infusion, the mean serum
bicarbonate decreased concomitantly with an equivalent increase
in plasma lactate, suggesting that all of the bicarbonate decrease
was due to acid buffering from the production of lactate. Studies
of ketogenesis during ritodrine and terbutaline infusion did not
show any changes in women treated with these agents for preterm
labor [26—28]. The mean venous pH in our patients was 7.35 and
this did not change at any time over the first four hours of drug
infusion, suggesting that increases in pulmonary ventilation oc-
curred appropriately to compensate for the decrease in serum
bicarbonate. A venous pH of 7.35 is consistent with venous pH
levels in normal pregnant women [43]. The plasma lactate/
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pyruvate ratio remained 10 to I throughout the first four hours of
drug infusion, suggesting that the cause for hyperlactatemia was
either overproduction of lactate or under utilization of pyruvate.
Women in labor may produce lactate but not to the levels seen in
our study [44]. In addition, stimulation of B-adrenergic muscle
receptors activates muscle phosphorylase, which induces muscle
glycogenolysis and leads to increased production of pyruvate
through the Embden-Myerhoff pathways [45]. We have previously
demonstrated overproduction of lactic acid due to B-adrenergic
drugs used to treat acute bronchospasm [46] and lactic acidosis
has been found in catecholamine excess states, such as pheochro-
mocytoma [47]. Thus, changes in acid-base homeostasis occur
during ritodrine and terbutaline infusion but do not contribute to
hypokalemia induced by these agents.
The pre-drug plasma renin activity and plasma aldosterone
levels were increased above non-pregnant levels to levels found in
normal pregnancies [48]. Plasma renin activity increased signifi-
cantly during drug infusions either due to activation of barore-
ceptor mechanisms in afferent arterioles due to B2-mediated
vasodilation or due to direct stimulation of renin release by
B-adrenergic-mediated mechanisms [49—Si]. Plasma aldosterone
levels fluctuated during drug infusions and changes were not
statistically significant. Moreover, changes in plasma aldosterone
were not associated with increased renal potassium excretion.
Increased urinary excretion of potassium was not a factor in
ritodrine- and terbutaline-induced hypokalemia. Rather, urinary
potassium excretion decreased and remained below baseline for
the 12 hours of drug infusion. Epinephrine infusion into humans
significantly decreases urinary potassium excretion [22,52]. More-
over, decreased distal nephron potassium secretion may occur
during ritodrine and terbutaline, since in vitro studies of the
isolated perfused cortical collecting tubule demonstrated that
isoproterenol directly inhibits potassium secretion [53]. In addi-
tion, the decreased urinary flow rate during drug infusion could
have limited urinary potassium excretion. Thus, despite the high
levels of plasma aldosterone in pregnant women treated with
ritodrine or terbutaline, urinary potassium excretion was signifi-
cantly diminished.
Urinary sodium and chloride excretion were significantly de-
creased during intravenous ritodrine and terbutaline. Several
mechanisms may have contributed to these changes. A decrease in
glomerular filtration rate may have decreased the filtered load of
sodium. In addition, B-adrenergic receptors may modulate prox-
imal tubule sodium reabsorption. Infusion of norepinephrine or
epinephrine into isolated perfused rat kidney induced sodium
retention that was blocked by propanolol but not by phenoxyben-
zamine, suggesting that sodium reabsorption is mediated by
B-adrenergic receptors [54]. In addition, in vitro experiments in
proximal tubular epithelia demonstrated beta-adrenergic in-
creases in fluid absorption and Na,K-ATPase activity [55—57].
Thus, it is possible that part of the decrease in sodium excretion
from these drugs may be secondary to B-adrenergic stimulation of
proximal tubular sodium reabsorption.
An increase in plasma renin activity during drug infusion would
lead to increases in plasma angiotensin Ii, which could also effect
sodium excretion in these patients. Although angiotensin ii
resistance occurs in the first and second trimester, probably due to
increased production of vasodilatory prostaglandins from the
placenta, partial vascular sensitivity to angiotensin II returns in
the third trimester [58]. Several studies suggest that angiotensin II
mediates sodium reabsorption in the mammalian kidney. Angio-
tensin IL infusion in dogs produces sodium retention without any
measurable changes in renal blood flow or glomerular filtration
rate [59]. In addition, micropuncture and isolated proximal tubule
perfusion studies demonstrated direct stimulation by angiotensin
II on proximal tubule sodium reabsorption [60]. Finally, intrave-
nous infusion of angiotensin II into normal humans decreases the
fractional excretion of lithium, a marker of proximal tubule
sodium reabsorption [61]. Thus, it is possible that sodium reten-
tion in women treated with ritrodine or terbutaline could be
secondary to the direct renal hemodynamic effects of these drugs,
or due to a direct B-adrenergic or angiotensin II effect to
stimulate proximal tubule sodium reabsorption.
The decrease in urinary flow rate and significant increase in
urinary osmolality suggest that enhanced antidiuretic hormone
secretion occurs during infusion of ritrodine or terbutaline. In-
deed, the mechanism of B-adrenergic decreases in renal water
excretion in humans and animals is secondary to non-osmotic
stimulation of ADH. Beta-adrenergic-induced vasodilation de-
creases carotid and aortic baroreceptor tone leading to increased
ADH release from the hypothalamus [62]. ADH levels were not
measured in this study, but fenoterol, an experimental beta-
adrenergic tocolytic significantly increased plasma ADH levels
and decreased urinary water excretion [54]. The reduced renal
sodium, chloride and water excretion during the first 12 hours of
intravenous infusion of ritodrine and terbutaline in our study may
contribute to the onset of pulmonary edema in women receiving
these agents [8].
In conclusion, ritodrine and terbutaline may induce hyperlac-
tatemia and significant hypokalemia leading to cardiac arrhyth-
mias in women treated with these agents for preterm labor.
Significant arrhythmias may occur when plasma potassium de-
creases to < 2.5 mEq/liter. Significant sodium and fluid retention
can also occur, possibly contributing to pulmonary edema induced
by these drugs. Most of these effects occurs within six hours of
initiating tocolytic therapy. Cardiac monitoring should be initiated
for any pregnant woman in preterm labor treated with intravenous
ritodrine or terbutaline. In addition, the blood potassium should
be checked two to four hours after initiation of drug therapy to
identify those women prone to severe hypokalemia, who may
benefit from potassium supplementation. Further studies compar-
ing subcutaneous versus intravenous terbutaline and ritodrine to
treat preterm labor are needed to determine whether the side
effects of these agents can be minimized while still providing
therapeutic efficacy.
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